Phase I Trial of an Oral Immunomodulator and Interferon Inducer in Cancer Patients

Cancer Research

Volumn 53, Issue 21, 1993, Pages 5176-5180

  Witt, Patricia L ^a   Ritch, Paul S ^a   Reding, Douglas ^b   McAuliffe, Timothy L ^a   Westrick, Linda ^a   Grossberg, Sidney E ^a   Borden, Ernest C ^a  

^a MEDICAL COLLEGE OF WISCONSIN   (United States)

^b MARSHFIELD CLINIC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

1 (2 METHYLPROPYL) 1H IMIDAZO[4,5C]QUINOLIN 4 AMINE; 2',5' OLIGOADENYLATE SYNTHETASE; ALPHA INTERFERON; ANTIBODY; BETA 2 MICROGLOBULIN; CYTOKINE; IMMUNOMODULATING AGENT; INTERLEUKIN 1BETA; NEOPTERIN; PROTEIN; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG;

ADULT; AGED; ARTICLE; BLOOD LEVEL; CLINICAL ARTICLE; ENZYME LINKED IMMUNOSORBENT ASSAY; FATIGUE; FEMALE; FEVER; HEADACHE; HUMAN; LYMPHOCYTOPENIA; MALAISE; MALE; MALIGNANT NEOPLASTIC DISEASE; ORAL DRUG ADMINISTRATION; PRIORITY JOURNAL; PROTEIN INDUCTION; RADIOIMMUNOASSAY; TUMOR GROWTH;

2',5'-OLIGOADENYLATE SYNTHETASE; ADMINISTRATION, ORAL; AMINOQUINOLINES; AUTOANTIBODIES; BETA 2-MICROGLOBULIN; BIOPTERIN; DRUG ADMINISTRATION SCHEDULE; DRUG MONITORING; HUMAN; INTERFERON INDUCERS; INTERFERON-ALPHA; NEOPLASM STAGING; NEOPLASMS; NEOPTERIN; SUPPORT, NON-U.S. GOV'T; SUPPORT, U.S. GOV'T, P.H.S.; TUMOR NECROSIS FACTOR;

EID: 0027420347     PISSN: 00085472     EISSN: 15387445     Source Type: Journal    
DOI: None     Document Type: Article

References (33)

1. Weeks, C. E. and Reiter, M. J. Antiviral/immunomodulator R-837 induces alpha interferon in mice. J. Invest. Dermatol., 93: 584, 1989.
2. Gibson, S. J., Elrod, S. V., Miller, R. L. and Weeks, C. E. Oral R-837 induced alpha interferon in cynomolgus monkeys. J. Interferon Res., 10: S124, 1990.
3. Sidky, Y. A., Borden, E. C., Weeks, C. E., Reiter, M. J., Hatcher, J. F. and Bryan, G. T. Inhibition of murine tumor growth by an interferon-inducing imidazoquinolinamine. Cancer Res., 52: 3528-3533, 1992.
4. Harrison, C. J., Jenski, L., Voychehovski, T. and Bernstein, D. I. Modification of immunological responses and clinical disease during topical R-837 treatment of genital HSV-2 infection. Antiviral Res., 10: 209-224, 1988.
5. Bernstein, D. I. and Harrison, C. J. Effects of the immunomodulating agent R837 on acute and latent herpes simplex virus type 2 infections. Antimicrob. Agents Chemother., 33: 1511-1515, 1989.
6. Weeks, C. E. and Gibson, S. J. Alpha interferon induction in human blood cell culture by immunomodulator candidate R-837. J. Interferon Res., 9: S215, 1989.
7. Grossberg, S. E., Taylor, J. L., Siebenlist, R. E. and Jameson, P. Biological and immunological assays of human interferons. In: N. R., Rose, H., Friedman, and J. L. Fahey (eds.), Manual of Clinical Laboratory Immuology, 3rd ed. pp. 295-299. Washington, DC: American Society for Microbiology, 1986.
8. WHO Expert Committee on Biological Standardization. 1983. Standardization of Interferons: WHO Technical Report Series No. 687. World Health Organization, Geneva.
9. Merritt, J. A., Borden, E. C. and Ball, L. A. Measurement of 2′,5′ oligo-adenylate synthetase in patients receiving interferon-alpha. J. Interferon Res. 5:191-198,1985.
10. Witt, P. L., Spear, G. T., Helgeson, D. O., Lindstrom, M. J., Smalley, R. V. and Borden, E. C. Basal and interferon-induced 2′5′-oligoadenylate synthetase in human monocytes, lymphocytes and peritoneal macrophages. J. Interferon Res., 10: 393-402, 1990.
11. Quesada, J. R., Hawkins, M., Horning, S., Alexanian, R., Borden, E., Merigan, T., Adams, F. and Gutterman, J. U. Collaborative phase MI study of recombinant DNA-produced leukocyte interferon (clone A) in metastatic breast cancer, malignant lymphoma, and multiple myeloma. Am. J. Med., 77: 427-432, 1984.
12. Gutterman, J. U., Fine, S., Quesada, J., Horning, S. J., Levine, J. F., Alexanian, R., Bernhardt, L., Kramer, M., Spiegel, H., Colburn, W., Trown, P., Merigan, T. and Dziewanowski, Z. Recombinant leukocyte A interferon: pharmacokinetics, single-dose tolerance, and biologic effects in cancer patients. Ann. Intern. Med., 96: 549-555, 1982.
13. Hawkins, M. J., Borden, E. C., Merritt, J. A., Edwards, B. S., Ball, L. A., Grossbard, E. and Simon, K. J. Comparison of the biologic effects of two recombinant human interferons alpha (rA and rD) in humans. J. Clin. Oncol., 2: 221-226, 1984.
14. Bever, C. T., McFarland, H. F., McFarlin, D. E. and Levy, H. B. The kinetics of interferon induction by poly ICLC in humans. J. Interferon Res., 8: 419-425, 1988.
15. Lampkin, B. C., Levine, A. S., Levy, H., Krivit, W. and Hammond, D. Phase II trial of a complex polyriboinosinic-polyribocytidylic acid with poly-L-lysine and carboxy-methyl cellulose in the treatment of children with acute leukemia and neuroblastoma: a report from the Children's Cancer Study Group. Cancer Res. 45:5904-5909,1985.
16. Krown, S. E., Kerr, D., Stewart, W. E., II, Pollack, M. S. Cunningham-Rundles, S., Hirshaut, Y., Pinsky, C. M., Levy, H. B. and Oettgen, H. F. Phase I trial of poly ICLC in patients with advanced cancer. In: E. M. Hersh, M. A., Chirigos, and M. J. Mastrangelo (eds.), Augmenting Agents in Cancer Therapy, pp. 165-176. New York: Raven Press, 1981.
17. Ewel, C. H., Urba, W. J., Kopp, W. C., Smith, J. W., II, Steis, R. G., Rossio, J. L., Longo, D. L., Jones, M. J., Alvord, W. G., Pinsky, C. M., Beveridge, J. M., McNitt, K. L. and Creekmore, S. P. Polyinosinic-polycytidylic acid complexed with poly-L-lysine and carboxymethylcellulose in combination with interleukin 2 in patients with cancer: clinical and immunological effects. Cancer Res., 52: 3005-3010, 1992.
18. Hovanessian, A. G., Youn, J. K. Buffet-Janvresse, C., Riviere, Y., Michelson, M., Lacour, J. and Lacour, F. Enhancement of natural killer cell activity and 2-5A synthetase in operable breast cancer patients treated with polyadenylic:polyuridylic acid. Cancer (Phila.), 55: 357-362, 1985.
19. Mace, K. F., Hornung, R. L., Wiltrout, R. H. and Young, H. A. Correlation between in vivo induction of cytokine gene expression by flavone acetic acid and strict dose dependency and therapeutic efficacy against murine renal cancer. Cancer Res., 50: 1742-1747, 1990.
20. Futami, H., Eader, L. A., Back, T. T., Gruys, E., Young, H. A., Wiltrout, R. H. and Baguley, B. C. Cytokine induction and therapeutic synergy with interleukin-2 against murine renal and colon cancers by xanthenone-4-acetic acid derivatives. J. Immunother., 12: 247-255, 1992.
21. Weiss, R. B., Greene, R. F., Knight, L. D., Collins, J. M., Pelosi, A., Sulkes, J. J. and Curt, G. A. Phase I and clinical pharmacology study of intravenous flavone acetic acid. Cancer Res., 48: 5878-5882, 1988.
22. Futami, H., Eader, L. A., Komschlies, K. L., Bull, R., Grays, E., Ortaldo, J. R., Young, H. A. and Wiltrout, R. H. Flavone acetic acid directly induces expression of cytokine genes in mouse splenic leukocytes but not in human peripheral blood leukocytes. Cancer Res., 51: 6596-6602, 1991.
23. Freund, M., VonWussow, P., Diedrich, H., Eisert, R., Link, H., Wilke, H., Buchholz, F., LeBlanc, S., Fonatsch, C., Deicher, H. and Poliwoda, H. Recombinant human interferon (IFN) alpha-2b in chronic myelogenous leukaemia: dose dependence of response and frequency of neutralizing anti-interferon antibodies. Br. J. Haematol., 72: 350-356, 1989.
24. vonWussow, P., Pralle, H., Hochkeppel, H.-K., Jakschies, D., Sonnen, S., Schmidt, H. Müller-Rosenau, D., Franke, M., Haferlach, T., Zwingers, T., Rapp, U. and Deicher, H. Effective natural interferon-α therapy in recombinant interferon-α-resistant patients with hairy cell leukemia. Blood, 78: 38-43, 1991.
25. Steis, R. G., Smith, J. W., II, Urba, W. J., Clark, J. W., Itri, L. M., Evans, L. M., Schoenberger, C. and Longo, D. L. Resistance to recombinant interferon alpha-2a in hairy-cell leukemia associated with neutralizing anti-interferon antibodies. N. Engl. J. Med., 318: 1409-1413, 1988.
26. Oberg, K., Alm, G., Magnusson, A., Lundqvist, G., Theodorsson, E., Wide, L. and Wilander, E. Treatment of malignant carcinoid tumors with recombinant interferon alpha-2b: development of neutralizing interferon antibodies and possible loss of antitumor activity. J. Natl. Cancer Inst., 81: 531-535, 1989.
27. Krown, S. E., Mintzer, D. Cunninham-Rundles, S., Niedswiecki, D., Krim, M., Einzig, A. I., Gabrilove, J. L., Shurgot, B. and Gessula, J. High-dose human lymphoblastoid interferon in metastatic colorectal cancer: clinical results and modification of biological responses. Cancer Treat. Rep., 71: 39-45, 1987.
28. Borden, E. C., Rinehart, J. J., Storer, B. E., Trump, D. L., Paulnock, D. M. and Teitelbaum, A. P. Biological and clinical effects of interferon betaser at two doses. J. Interferon Res., 10: 559-570, 1990.
29. Witt, P. L., Storer, B. E., Bryan, G. T., Brown, R. R., Flashner, M., Larocca, A. T., Colby, C. B. and Borden, E. C. Pharmacodynamics of biological response in vivo after single and multiple doses of interferon-β. J. Immunother., 13: 191-200, 1993.
30. Tanaka, K., Yoshioka, T., Bieberich, C. and Jay, G. Role of the major histocompatibility complex class I antigens in tumor growth and metastasis. Annu. Rev. Immunol., 6: 359-380, 1988.
31. Lengyel, P. Biochemistry of interferons and their actions. Annu. Rev. Biochem., 57: 251-282, 1982.
32. Huber, G., Batchelor, J. R., Fuchs, D., Hausen, A., Lang, A., Niederwieser, D., Reibnegger, G., Swetly, P., Troppmair, J. and Wachter, H. Immune response-associated production of neopterin: release from macrophages primarily under control of IFN-gamma. J. Exp. Med., 160: 310-314, 1984.
33. Borden, E. C. Interferons—expanding therapeutic roles. N. Engl. J. Med., 326: 1491-1493, 1992.